HUP0302772A2 - 3-Fenil-5-alkoxi-1,3,4-oxadiazol-2-on-származékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyszerkészítmények - Google Patents
3-Fenil-5-alkoxi-1,3,4-oxadiazol-2-on-származékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0302772A2 HUP0302772A2 HU0302772A HUP0302772A HUP0302772A2 HU P0302772 A2 HUP0302772 A2 HU P0302772A2 HU 0302772 A HU0302772 A HU 0302772A HU P0302772 A HUP0302772 A HU P0302772A HU P0302772 A2 HUP0302772 A2 HU P0302772A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- optionally substituted
- general formula
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 102000000019 Sterol Esterase Human genes 0.000 title 1
- 108010055297 Sterol Esterase Proteins 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- -1 nitro- Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 abstract 1
- 102000004882 Lipase Human genes 0.000 abstract 1
- 108090001060 Lipase Proteins 0.000 abstract 1
- 239000004367 Lipase Substances 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000006267 biphenyl group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 235000019421 lipase Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
A találmány szubsztituált 3-fenil-5-alkoxi-1,3,4-oxadiazol-2-on-származékokra vonatkozik, melyek a hormonszelektív lipáz (HSL) gátlóhatással rendelkeznek. A találmány szerinti (1) általános képletűvegyületek képletében R1 jelentése adott esetben szubsztituált C1-C6-alkil-, C3-C9-cikloalkilcsoport és R2, R3, R4 és R5 jelentéseegymástól függetlenül hidrogénatom, halogénatom, nitro-, C1-C4-alkil-,C1-C9-alkoxicsoport; adott esetben szubsztituált C6-C10-aril-C1-C4-alkiloxi-, C6-C10-ariloxi-, C6-C10-aril-, C3-C8-cikloalkil- vagy O-C3-C8-cikloalkilcsoport; 2-oxo-pirrolidin-1-il-, 2,5-dimetilpirrol-1-il-vagy NR6-A-R7 általános képletű csoport, azzal a megkötéssel, hogy R2,R3, R4 és R5 közül legalább egynek a jelentése hidrogénatomtólkülönböző, és az R2, R3, R4 vagy R5 csoport közül legalább egynek ajelentése 2-oxo-pirrolidin-1-il-, 2,5-dimetilpirrol-1-il- vagy NR6-A-R7 általános képletű csoport; R6 jelentése hidrogénatom, C1-C4-alkil-vagy adott esetben szubsztituált C6-C10-aril-C1-C4-alkilcsoport; Ajelentése egyszeres kötés, COn, SOn vagy CONH képletű csoport; nértéke 1 vagy 2; R7 jelentése hidrogénatom; adott esetbenszubsztituált C1-C18-alkil, C2-C18-alkenil, C6-C10-aril-C1-C4-alkil-,C5-C8-cikloalkil-C1-C4-alkil-, C5-C8-cikloalkil-, C6-C10-aril-C2-C6-alkenil-, C6-C10-aril-, difenil-, difenil-C1-C4-alkil-, indanil-, vagyHet- (CH2)r- általános képletű csoport - ahol r=0, 1, 2 vagy 3 és Hetjelentése telítetlen vagy telített 5-7-tagú heterociklus, amelybenzollal anellált és adott esetben szubsztituált; valamint ezekgyógyászatilag elfogadható és savaddíciós sói. A találmány továbbitárgya eljárás az (1) általános képletű vegyületek előállítására. Atalálmány további tárgyát képezi gyógyszerkészítmény nem inzulinfüggődiabetes mellitus vagy diabetikus tünetek kezelésére, amely az (1)általános képletű vegyületet tartalmazza. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000110968 DE10010968A1 (de) | 2000-03-07 | 2000-03-07 | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| DE2001102265 DE10102265C1 (de) | 2001-01-18 | 2001-01-18 | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| PCT/EP2001/001898 WO2001066531A1 (de) | 2000-03-07 | 2001-02-20 | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302772A2 true HUP0302772A2 (hu) | 2003-11-28 |
| HUP0302772A3 HUP0302772A3 (en) | 2007-03-28 |
Family
ID=26004720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302772A HUP0302772A3 (en) | 2000-03-07 | 2001-02-20 | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6369088B2 (hu) |
| EP (1) | EP1263745B1 (hu) |
| JP (1) | JP2003525931A (hu) |
| KR (1) | KR100790763B1 (hu) |
| CN (1) | CN1261419C (hu) |
| AR (1) | AR027611A1 (hu) |
| AT (1) | ATE267184T1 (hu) |
| AU (1) | AU784827B2 (hu) |
| BR (1) | BR0108974A (hu) |
| CA (1) | CA2401953A1 (hu) |
| DE (1) | DE50102325D1 (hu) |
| DK (1) | DK1263745T3 (hu) |
| EE (1) | EE04877B1 (hu) |
| ES (1) | ES2218383T3 (hu) |
| HK (1) | HK1054036B (hu) |
| HR (1) | HRP20020732A2 (hu) |
| HU (1) | HUP0302772A3 (hu) |
| IL (1) | IL151518A (hu) |
| MX (1) | MXPA02008038A (hu) |
| NO (1) | NO323483B1 (hu) |
| NZ (1) | NZ521207A (hu) |
| PL (1) | PL359702A1 (hu) |
| PT (1) | PT1263745E (hu) |
| RU (1) | RU2281283C2 (hu) |
| SK (1) | SK12752002A3 (hu) |
| TR (1) | TR200401217T4 (hu) |
| WO (1) | WO2001066531A1 (hu) |
| YU (1) | YU57802A (hu) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| DE10208986A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase |
| US6900233B2 (en) | 2002-02-28 | 2005-05-31 | Aventis Pharma Deutschland Gmbh | Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof |
| DE10208987A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| US20030236288A1 (en) * | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| US20090082435A1 (en) * | 2005-04-28 | 2009-03-26 | The Regents Of The University Of California | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders |
| CN101225085B (zh) * | 2007-01-17 | 2011-09-21 | 天津天士力集团有限公司 | 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途 |
| TW201033163A (en) * | 2008-10-20 | 2010-09-16 | Sumitomo Chemical Co | Method for manufacturing oxadiazolinone compound and intermediate thereof |
| WO2010074587A2 (en) | 2008-12-23 | 2010-07-01 | Bial - Portela & Ca., S.A. | 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use |
| EP2543660A4 (en) * | 2010-03-04 | 2014-04-30 | Ajinomoto Kk | PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| US9278910B2 (en) | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| JP6061949B2 (ja) | 2011-12-12 | 2017-01-18 | レセプトス エルエルシー | 糖尿病などの疾患の治療のためのｇｌｐ−１受容体モジュレーターとして作用する４つの環を含むカルボン酸誘導体 |
| EA030857B1 (ru) | 2013-06-11 | 2018-10-31 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
| SG11201700364PA (en) | 2014-07-25 | 2017-02-27 | Celgene Internat Ii Sarl | Novel glp-1 receptor modulators |
| EP3230276B1 (en) | 2014-12-10 | 2020-09-02 | Celgene International II Sarl | Glp-1 receptor modulators |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| CN108863774A (zh) * | 2018-06-09 | 2018-11-23 | 石家庄市绿丰化工有限公司 | 一种2,4-二氯苯乙酰氯合成的方法 |
| CA3119912A1 (en) | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2299028A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Nouvea |
| US4076824A (en) | 1975-02-03 | 1978-02-28 | Rhone-Poulenc Industries | Anthelmintic oxadiazolinone derivatives |
| FR2299328A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Derives de l'alcoyloxy-5 phenyl-3 oxyde azo |
| DK156439C (da) | 1980-09-15 | 1990-01-22 | Shell Int Research | 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer |
| DE3267258D1 (en) | 1981-06-15 | 1985-12-12 | Shell Int Research | 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates |
| DE3931843A1 (de) | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
| US5236939A (en) | 1989-09-23 | 1993-08-17 | Bayer Aktiengesellschaft | Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
-
2001
- 2001-02-20 EP EP01905805A patent/EP1263745B1/de not_active Expired - Lifetime
- 2001-02-20 KR KR1020027011634A patent/KR100790763B1/ko not_active IP Right Cessation
- 2001-02-20 IL IL151518A patent/IL151518A/en not_active IP Right Cessation
- 2001-02-20 JP JP2001565347A patent/JP2003525931A/ja not_active Abandoned
- 2001-02-20 EE EEP200200498A patent/EE04877B1/xx not_active IP Right Cessation
- 2001-02-20 TR TR2004/01217T patent/TR200401217T4/xx unknown
- 2001-02-20 WO PCT/EP2001/001898 patent/WO2001066531A1/de active IP Right Grant
- 2001-02-20 CA CA002401953A patent/CA2401953A1/en not_active Abandoned
- 2001-02-20 NZ NZ521207A patent/NZ521207A/en unknown
- 2001-02-20 AU AU33787/01A patent/AU784827B2/en not_active Ceased
- 2001-02-20 ES ES01905805T patent/ES2218383T3/es not_active Expired - Lifetime
- 2001-02-20 BR BR0108974-9A patent/BR0108974A/pt not_active IP Right Cessation
- 2001-02-20 RU RU2002126556/04A patent/RU2281283C2/ru not_active IP Right Cessation
- 2001-02-20 YU YU57802A patent/YU57802A/sh unknown
- 2001-02-20 MX MXPA02008038A patent/MXPA02008038A/es active IP Right Grant
- 2001-02-20 PT PT01905805T patent/PT1263745E/pt unknown
- 2001-02-20 DK DK01905805T patent/DK1263745T3/da active
- 2001-02-20 HU HU0302772A patent/HUP0302772A3/hu unknown
- 2001-02-20 SK SK1275-2002A patent/SK12752002A3/sk unknown
- 2001-02-20 PL PL35970201A patent/PL359702A1/xx not_active IP Right Cessation
- 2001-02-20 DE DE50102325T patent/DE50102325D1/de not_active Expired - Lifetime
- 2001-02-20 AT AT01905805T patent/ATE267184T1/de not_active IP Right Cessation
- 2001-02-20 CN CNB018062156A patent/CN1261419C/zh not_active Expired - Fee Related
- 2001-03-05 AR ARP010101037A patent/AR027611A1/es not_active Application Discontinuation
- 2001-03-06 US US09/799,082 patent/US6369088B2/en not_active Expired - Lifetime
-
2002
- 2002-09-03 NO NO20024201A patent/NO323483B1/no unknown
- 2002-09-05 HR HRP20020732 patent/HRP20020732A2/hr not_active Application Discontinuation
-
2003
- 2003-09-09 HK HK03106394.6A patent/HK1054036B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302772A2 (hu) | 3-Fenil-5-alkoxi-1,3,4-oxadiazol-2-on-származékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyszerkészítmények | |
| RU2411239C2 (ru) | Органические соединения | |
| JO2282B1 (en) | Oxazole derivatives | |
| CA2550128A1 (en) | Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases | |
| HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
| HUP0303891A2 (hu) | Gyógyhatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0101281A2 (hu) | Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0102471A2 (hu) | 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények | |
| WO2000021927A3 (en) | Pyrrole-2,5-diones as gsk-3 inhibitors | |
| HUP0301351A2 (hu) | Helyettesített dipeptidszármazékok eljárás az előállításukra alkalmazásuk növekedési hormon szekretagóg hatóanyagokként, és ezeket tartalmazó gyógyszerkészítmények | |
| HUP9900172A2 (hu) | Idegrendszeri elváltozások kezelésére alkalmas 10-aciloxi-10,11-dihidrobenz/b,f/azepin-5-karboxamid, előállítása és ezt tartalmazó gyógyszerkészítmény | |
| NO20056010L (no) | Biaryloksymetylaren-karboksylsyrer | |
| JP2006507326A5 (hu) | ||
| ATE473967T1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| CA2279319C (en) | Benzofurazan compounds which enhance ampa receptor activity | |
| HUP0303281A2 (hu) | Benzodiazepinszármazékok, mint GABA A receptor modulátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE69332691D1 (de) | Substituierte 3-(aminoalkylamino)-1,2-benzisoxazole und verwandte verbindungen | |
| CA2206005A1 (en) | Aniline derivatives possessing an inhibitory effect of nitric oxide synthase | |
| DE50310161D1 (de) | Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| JP2005538111A5 (hu) | ||
| NO20045351L (no) | 1-[(indol-3-yl)karbonyl] piperazin-derivater | |
| SE9701304D0 (sv) | Compounds | |
| JP2015522592A5 (hu) | ||
| TW201111375A (en) | N-substituted cyclic amino derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |